Navigation Links
Anemia drug not helpful for kidney disease patients
Date:12/22/2009

DALLAS Dec. 22, 2009 An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising.

Darbepoetin alfa is one of a class of drugs used to increase red blood cells in patients with type 2 diabetes, chronic kidney disease and anemia, but in a study of 4,038 patients, it did little to reduce cardiovascular problems, death or even the need for dialysis.

Patients have used the drug and other similar drugs for at least a decade to improve the symptoms of anemia.

"We were disappointed that the drug didn't make a difference," said Dr. Robert Toto, professor of internal medicine at UT Southwestern and senior author of the study in The New England Journal of Medicine. "We set out doing this trial to prove whether treatment of anemia would help our patients."

Researchers also found that subjects who took the drug were nearly twice as likely to have a stroke as those who received a placebo 101 subjects compared with 53.

"This is a surprise," Dr. Toto said. "Clinicians should not expect that treatment of anemia with darbepoetin and other drugs in its class will reduce their risk of cardiovascular events or prevent their kidney disease from progressing. If a clinician is treating a patient for fatigue and other symptoms of anemia and the symptoms do not improve, they should consider stopping the drug, because it may expose the patient to increased risk of stroke."

Chronic kidney disease, type 2 diabetes and anemia affect about 1 million people in the U.S., he said. Drugs such as darbepoetin alfa for treating anemic patients on dialysis (in the final stage of kidney disease) were approved in the late 1980s. Soon afterward, accepted guidelines suggested using the drug with chronic kidney disease patients not on dialysis in hopes of improving symptoms, cardiovascular death rates and preventing chronic kidney disease from progressing to dialysis.

While studies were done in an attempt to determine optimal hemoglobin levels using such drugs in these patients, no trial was conducted comparing the drug with a placebo, until TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy.

"From a scientific perspective, TREAT is the most rigorous," Dr. Toto said. "It's a randomized, double-blind, placebo-controlled trial."

From August 2005 until March 2009, researchers from 24 countries gave subjects with chronic kidney disease, type 2 diabetes or anemia either a placebo or darbepoetin alfa. Twenty four subjects were from UT Southwestern.

Cardiac death or events occurred in 31 percent of the darbepoetin alfa group and in 29 percent of the placebo group. Kidney disease death or progression to dialysis occurred in 32 percent of the darbepoetin alfa group and in 31 percent of the placebo group.

Researchers did find a modest decrease in reported fatigue levels and a decrease in the need for blood transfusion in subjects taking darbepoetin alfa.


'/>"/>

Contact: LaKisha Ladson
lakisha.ladson@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Anemia Drugs May Cause Deadly Blood Clots
2. Drugs to treat anemia in cancer patients linked to thromboembolism
3. Will New Anemia Drug Top Current Treatments?
4. Anemia Drug May Raise Stroke Risk in Kidney Patients
5. Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
6. Replication at DNA damage sites highlights Fanconi anemia and breast cancer proteins
7. How to confirm the causes of iron deficiency anemia in young women
8. Anemia associated with greater risk of death in heart disease patients
9. Researchers identify the gene responsible for a rare form of congenital anemia
10. Anemia Drugs May Raise Death Risk in Cancer Patients
11. Drugs to combat anemia in cancer patients increase risk of death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... Groove Ring is excited to announce they've ... performance silicon wedding bands and all-purpose rings. Whether you’re an athlete, adventurer, professional, or ... just for you. , From the rock face to the auto shop, Groove Ring ...
(Date:6/22/2017)... ... 2017 , ... Vighter, a premier provider of Unconventional Medical ... PSC.1-2012. The company’s work in countries throughout Southwest Asia, South America, and the ... degraded. The PSC.1 standard was created to protect fundamental freedoms and human rights ...
(Date:6/20/2017)... ... 20, 2017 , ... Connance, a leading provider of healthcare ... predictive analytics drive reimbursement optimization, with a focus on denial management and claims ... “The traditional approach to denied and underpaid claims leaves money on the table ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... has published a new eBook titled “ 5 Questions to Ask Before Entering ... Analyst on the Genetic Test Evaluation (GTE) team, the book explores the various ...
(Date:6/20/2017)... ... , ... HOUSTON – Brazos Towers at Bayou Manor is proud to ... for today’s modern senior. Brazos Towers at Bayou Manor has more than 50 years ... them the services to support that lifestyle both now and in the future. Instead ...
Breaking Medicine News(10 mins):
(Date:6/10/2017)...  Shane K. Burchfield, DPM, is recognized by Continental Who,s Who ... in Alabama . Dr. Burchfield ... He brings over 20 years of experience, as well as expertise ... his role. "The ... to welcome you to his practice," the company,s website ...
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ... Joseph R. Goodwin , U.S. District Court Judge ... , entered a case management order in MDL ... Liability Litigation (the "MDL") that includes a provision requiring ... disclosures on specific causation within one hundred twenty (120) ...
Breaking Medicine Technology: